Chemotherapy and radiation for returning esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests if adding radiation before and after standard chemotherapy can help people whose esophageal cancer has come back after initial treatment. It aims to improve control of the cancer while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have esophageal cancer that has come back in the same area after your first treatment with chemotherapy and radiation.
- The cancer may have spread to nearby lymph nodes, but not to distant parts of the body.
- You cannot have surgery to remove the cancer (or you choose not to have surgery).
- You must be healthy enough to handle chemotherapy, radiation, and immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiation therapy after initial chemoimmunotherapy improves outcomes for people with locally advanced esophageal cancer. It is designed for patients whose tumors are still responding or stable after the first treatment.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial is testing whether giving a combination of an immunotherapy drug (sintilimab) with chemotherapy, followed by radiation plus more chemotherapy (concurrent chemoradiotherapy), can help people with advanced esophageal cancer that cannot be removed surgically. The goal is to see if this approach shrinks the tumor and improves outcomes.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
This trial tests whether giving immunotherapy after surgery can help prevent cancer from returning in patients with esophageal squamous cell carcinoma. It is for people who have already received chemotherapy and immunotherapy before surgery and had surgery to remove the cancer, but still had some cancer cells found in the removed tissue.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.